Medtech CEOs Herbert, Elsesser on Meeting the Challenges of Leading Companies from Start-Up to IPO

06/07/18 • 23 min

CEOs often are assigned skill sets that define their stage of specialty: start-up CEOs, commercial CEOs, etc. Two of our guests at the Medtech Conference in Minneapolis defied those definitions by taking start-ups through commercial launches and onto the public markets. In these interviews, Tim Herbert of Inspire Medical and Adam Elsesser of Penumbra talk about the challenges of leading a company from Day 1 to IPO.

Previous Episode

Healthegy's Medtech Conference Bringing Together Pols, VCs and Executives to Discuss Sector's Future

Join us on Thursday at the Medtech Conference in Minneapolis to hear from Congressman Erik Paulsen.
A longtime proponent of the Medtech industry, Rep. Paulsen most recently co-authored a letter asking the Trump administration to remove medical technology products from a list of Chinese imports subject to protective tariffs.
The five-term Congressman also has fought against the Medical Device Tax.
The Medtech Conference co-chairs and advisory board also are pleased to honor Dave Amerson, CEO of NeoTract, as the recipient of this year’s Dealmaker of the Year Award.
The award recognizes Amerson's leadership of the urology start-up as it established its UroLift System as a critical treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Sales of UroLift were surging when Teleflex agreed to acquire the company, paying $725 million up front with the promise of another $375 million in milestone payments over the next two years.
In an interview, Justin Klein, general partner of NEA, and Amerson will discuss:

The steps Neotract took to adopt a winning culture?
What strategies helped the company secure support from payers, providers?
How the deal with Teleflex came to be?
What's next for Teleflex in Urology?

Join us on May 31st to explore this singular successful story and to better understand our entire Medtech sector.

Next Episode

CEO John Pedersen Explains Why Urology – and Augmenix – Are Enjoying Such an “Interesting Time”

In this Medtech Talk Podcast, CEO John Pedersen explains why he chose to help Augmenix roll out its SPACEOAR implant, a hydrogel that's inserted between a patient's prostate and rectum to save healthy tissue from radiation exposure. In this talk, Pedersen discusses the rise of urology - which includes the recent acquisitions of Neotract and NxThera. He also updates listeners on Augmenix's efforts to secure reimbursement. Finally, the former Boston Scientific exec offers advice to anyone working in a global Medtech company.